Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

54.38
-1.0100-1.82%
Post-market: 54.22-0.1600-0.29%17:38 EDT
Volume:2.66M
Turnover:145.16M
Market Cap:10.51B
PE:143.49
High:55.66
Open:55.30
Low:53.93
Close:55.39
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.99
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.66
PE(LYR):30.21

Loading ...

Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Oct 09

BioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR

TIPRANKS
·
Oct 09

BioMarin Submits FDA sNDA for Voxzogo in Hypochondroplasia

Reuters
·
Oct 09

BioMarin Expects Alesta Acquisition to Cut Full-Year 2026 GAAP, Non-GAAP Diluted EPS by About $1.55

Reuters
·
Oct 07

Biomarin Pharmaceutical - Expects $1.5 Unfavorable Impact to Gaap and Non-Gaap Diluted EPS for Q3 2026 - SEC Filing

THOMSON REUTERS
·
Oct 07

Biomarin Pharmaceutical - Expects Q3 2026 Pre-Tax Charges of $283 Mln for Bought Ipr&D Expense - SEC Filing

THOMSON REUTERS
·
Oct 07

Biomarin Appoints Cara Bauer as Chief People Officer

THOMSON REUTERS
·
Oct 06

Press Release: BioMarin Appoints Cara Bauer as Chief People Officer

Dow Jones
·
Oct 06

BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA

TIPRANKS
·
Oct 02

BioMarin Reports Five-Year Phase 3 Propel Extension Data for Pombiliti Plus Opfolda in Late-Onset Pompe Disease

Reuters
·
Oct 02

BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration

Simply Wall St.
·
Oct 01

Biomarin Pharmaceutical Enters Settlement and License Agreement with Ascendis Pharma on Sept 24, 2026

Reuters
·
Oct 01

Biomarin Pharmaceutical - Co and Ascendis to Dismiss All Pending Litigation with Prejudice - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% US, 18% EU/Br/SK Royalty on Sales Until May 2030 - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Grants Ascendis License for Transcon Cnp, Navepegritide, Yuviwel - SEC Filing

THOMSON REUTERS
·
Oct 01

BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products

Reuters
·
Oct 01

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Biomarin Pharmaceutical Inc. : JP Morgan Raises Target Price to $86 from $80

THOMSON REUTERS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17